Daymark Wealth Partners LLC Buys 6,430 Shares of CVS Health Co. (NYSE:CVS)

Daymark Wealth Partners LLC increased its stake in CVS Health Co. (NYSE:CVS - Free Report) by 24.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,967 shares of the pharmacy operator's stock after acquiring an additional 6,430 shares during the period. Daymark Wealth Partners LLC's holdings in CVS Health were worth $2,233,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. LaFleur & Godfrey LLC increased its holdings in CVS Health by 49.9% during the 4th quarter. LaFleur & Godfrey LLC now owns 4,836 shares of the pharmacy operator's stock valued at $217,000 after purchasing an additional 1,610 shares during the period. Vest Financial LLC raised its holdings in shares of CVS Health by 18.3% during the fourth quarter. Vest Financial LLC now owns 9,630 shares of the pharmacy operator's stock valued at $432,000 after acquiring an additional 1,492 shares in the last quarter. Moloney Securities Asset Management LLC lifted its stake in CVS Health by 2.7% in the fourth quarter. Moloney Securities Asset Management LLC now owns 27,305 shares of the pharmacy operator's stock worth $1,226,000 after acquiring an additional 708 shares during the period. Empirical Finance LLC boosted its holdings in CVS Health by 17.8% in the fourth quarter. Empirical Finance LLC now owns 52,588 shares of the pharmacy operator's stock valued at $2,361,000 after acquiring an additional 7,959 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new position in CVS Health in the 4th quarter worth $111,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Stock Up 0.5%

NYSE CVS traded up $0.35 during mid-day trading on Tuesday, reaching $64.21. The stock had a trading volume of 5,529,420 shares, compared to its average volume of 11,033,974. The company has a fifty day moving average price of $65.13 and a 200 day moving average price of $59.98. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. CVS Health Co. has a 1 year low of $43.56 and a 1 year high of $72.51. The stock has a market cap of $81.22 billion, a PE ratio of 17.54, a price-to-earnings-growth ratio of 0.98 and a beta of 0.56.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The firm had revenue of $94.59 billion for the quarter, compared to the consensus estimate of $93.07 billion. During the same period in the prior year, the company posted $1.31 earnings per share. The company's quarterly revenue was up 7.0% on a year-over-year basis. On average, research analysts expect that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were paid a $0.665 dividend. The ex-dividend date of this dividend was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.14%. CVS Health's dividend payout ratio (DPR) is currently 63.48%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on CVS shares. Wells Fargo & Company reaffirmed an "overweight" rating and set a $84.00 target price (up previously from $76.00) on shares of CVS Health in a research note on Tuesday, May 6th. Wall Street Zen raised CVS Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Royal Bank of Canada lifted their price target on CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a research report on Monday, May 5th. Wolfe Research increased their price objective on CVS Health from 67.00 to 70.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Finally, Leerink Partnrs upgraded shares of CVS Health from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $74.75.

Insider Buying and Selling

In other news, Director Guy P. Sansone purchased 1,570 shares of the business's stock in a transaction on Thursday, June 5th. The stock was acquired at an average cost of $63.70 per share, for a total transaction of $100,009.00. Following the purchase, the director now directly owns 12,007 shares in the company, valued at $764,845.90. This trade represents a 15.04% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.22% of the stock is currently owned by corporate insiders.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.